Metastatic Colorectal Cancer
Why trials studying Metastatic Colorectal Cancer stopped, in this sample of ClinicalTrials.gov.
23 stopped trials with a clear reason; 83% ended for non-scientific reasons.
| Reason | Trials | Share |
|---|---|---|
| slow enrollment | 7 | 30% |
| funding or business | 6 | 26% |
| staffing, sites or logistics | 5 | 22% |
| safety | 2 | 9% |
| other | 2 | 9% |
| drug or device supply | 1 | 4% |
Trials
- Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer
NCT06501989 · WITHDRAWN · staffing, sites or logistics
“Principal Investigator has left Inova” - Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)
NCT06603818 · WITHDRAWN · funding or business
“The trial is closing due to findings from a related study, prompting the sponsor to discontinue development and end this study.” - Niraparib Maintenance Treatment in mCRC With a Partial o Complete Response After Oxaliplatin-based Induction Therapy
NCT05412706 · WITHDRAWN · staffing, sites or logistics
“The Principal Investigator has retired and has not been replaced has retired and a new one has not been identified Principal Investigator” - Electroporation and Immunotherapy in Metastatic Colorectal Cancer
NCT05609656 · TERMINATED · safety
“The study was terminated on the basis on an evaluation of the efficacy and safety of the 4 included and treated patients.” - FUDR/Oxaliplatin HAI Plus Irinotecan vs. FOLFOXIRI Chemotherapy in Treating Initially Unresectable CRCLM
NCT03678428 · TERMINATED · drug or device supply
“Production halt of FUDR in China” - Sym004 Versus TAS-102 in Patients With mCRC
NCT03717038 · WITHDRAWN · staffing, sites or logistics
“Study was withdrawn due to administrative reasons” - Phase II Trial Assessing the Efficacy of Immuno-Radiation Abscopal Effect in Patients With Metastatic Cancers
NCT03323424 · WITHDRAWN · slow enrollment
“No patient enrolled during the authorized period” - Yttrium-90 Radioembolization + Nivolumab for Liver + Extra-hepatic Metastases From Colorectal Cancer
NCT03307603 · WITHDRAWN · funding or business
“Sponsor chose not to continue” - Sym004 Versus Futuximab or Modotuximab in Patients With mCRC
NCT03549338 · TERMINATED · staffing, sites or logistics
“Study was terminated due to administrative reasons” - SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer
NCT03645876 · TERMINATED · funding or business
“The study was terminated early due to company decision” - PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer
NCT03176264 · TERMINATED · funding or business
“The study was terminated early due to company decision.” - Phase II Trial of FOLFOXIGIL Versus FOLFOXIRI as First-line Therapy in Patients With mCRC
NCT03222089 · WITHDRAWN · other
“Another study enrolling the similar group of patient are ongoing” - Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer
NCT02654639 · TERMINATED · staffing, sites or logistics
“Principal investigator left the institution” - Abscopal Effect for Metastatic Colorectal Cancer
NCT02535988 · WITHDRAWN · slow enrollment
“No recruitment.” - Visualization of Anti-angiogenic Effects With Perfusion Computed Tomography (CTP)
NCT02511756 · TERMINATED · slow enrollment
“Slow accrual” - A Phase II Study of Ziv-aflibercept in Combination With Capecitabine/Oxaliplatin (XELOX) Chemotherapy in the Front-Line Treatment of Patients With Metastatic Colorectal Cancer
NCT02079220 · WITHDRAWN · funding or business
“Funding for the study was withdrawn, no participants were ever recruited.” - Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancer
NCT02605044 · TERMINATED · funding or business
“Sponsor decision based on portfolio prioritization” - A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer
NCT01925274 · TERMINATED · slow enrollment
“Enrollment to the study was terminated on 11Nvo2014 due to slow recruitment. There were no safety or efficacy issues that contributed to this decision.” - Hepatic Arterial Infusion With FOLFOX Alone or in Combination With IV Chemotherapy in Colon Cancer With Liver Metastasis
NCT02345746 · WITHDRAWN · slow enrollment
“patient population” - Cetuximab for Elderly Patients With mCRC
NCT01718808 · TERMINATED · other
“FU for 3 years from randomization as initially planned is stopped as we do not expect any changes to the endpoints in the future after one year of FU.” - 2nd-line Treatment of Metastatic Colorectal Cancer
NCT01532804 · TERMINATED · slow enrollment
“too slow recruiting” - Positron Emission Tomography - Computed Tomography (PET-CT) Cetuximab Project
NCT00828620 · TERMINATED · slow enrollment
“Lack of recruitment” - A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer
NCT00779311 · TERMINATED · safety
“Dose limiting toxicity at the lowest planned dose level.”
Reasons are labeled automatically and are unverified. See the methodology. This is research information, not medical advice. Search the full database.